Cargando…
Clinical results of stereotactic body radiotherapy for Stage I small-cell lung cancer: a single institutional experience
The purpose of this study was to evaluate the treatment outcomes of stereotactic body radiotherapy (SBRT) for Stage I small-cell lung cancer (SCLC). From April 2003 to September 2009, a total of eight patients with Stage I SCLC were treated with SBRT in our institution. In all patients, the lung tum...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3534277/ https://www.ncbi.nlm.nih.gov/pubmed/22923748 http://dx.doi.org/10.1093/jrr/rrs075 |
_version_ | 1782475306567729152 |
---|---|
author | Shioyama, Yoshiyuki Nakamura, Katsumasa Sasaki, Tomonari Ohga, Saiji Yoshitake, Tadamasa Nonoshita, Takeshi Asai, Kaori Terashima, Koutarou Matsumoto, Keiji Hirata, Hideki Honda, Hiroshi |
author_facet | Shioyama, Yoshiyuki Nakamura, Katsumasa Sasaki, Tomonari Ohga, Saiji Yoshitake, Tadamasa Nonoshita, Takeshi Asai, Kaori Terashima, Koutarou Matsumoto, Keiji Hirata, Hideki Honda, Hiroshi |
author_sort | Shioyama, Yoshiyuki |
collection | PubMed |
description | The purpose of this study was to evaluate the treatment outcomes of stereotactic body radiotherapy (SBRT) for Stage I small-cell lung cancer (SCLC). From April 2003 to September 2009, a total of eight patients with Stage I SCLC were treated with SBRT in our institution. In all patients, the lung tumors were proven as SCLC pathologically. The patients' ages were 58–84 years (median: 74). The T-stage of the primary tumor was T1a in two, T1b in two and T2a in four patients. Six of the patients were inoperable because of poor cardiac and/or pulmonary function, and two patients refused surgery. SBRT was given using 7–8 non-coplanar beams with 48 Gy in four fractions. Six of the eight patients received 3–4 cycles of chemotherapy using carboplatin (CBDCA) + etoposide (VP-16) or cisplatin (CDDP) + irinotecan (CPT-11). The follow-up period for all patients was 6–60 months (median: 32). Six patients were still alive without any recurrence. One patient died from this disease and one died from another disease. The overall and disease-specific survival rate at three years was 72% and 86%, respectively. There were no patients with local progression of the lesion targeted by SBRT. Only one patient had nodal recurrence in the mediastinum at 12 months after treatment. The progression-free survival rate was 71%. No Grade 2 or higher SBRT-related toxicities were observed. SBRT plus chemotherapy could be an alternative to surgery with chemotherapy for inoperable patients with Stage I small-cell lung cancer. However, further investigation is needed using a large series of patients. |
format | Online Article Text |
id | pubmed-3534277 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-35342772013-01-03 Clinical results of stereotactic body radiotherapy for Stage I small-cell lung cancer: a single institutional experience Shioyama, Yoshiyuki Nakamura, Katsumasa Sasaki, Tomonari Ohga, Saiji Yoshitake, Tadamasa Nonoshita, Takeshi Asai, Kaori Terashima, Koutarou Matsumoto, Keiji Hirata, Hideki Honda, Hiroshi J Radiat Res Oncology The purpose of this study was to evaluate the treatment outcomes of stereotactic body radiotherapy (SBRT) for Stage I small-cell lung cancer (SCLC). From April 2003 to September 2009, a total of eight patients with Stage I SCLC were treated with SBRT in our institution. In all patients, the lung tumors were proven as SCLC pathologically. The patients' ages were 58–84 years (median: 74). The T-stage of the primary tumor was T1a in two, T1b in two and T2a in four patients. Six of the patients were inoperable because of poor cardiac and/or pulmonary function, and two patients refused surgery. SBRT was given using 7–8 non-coplanar beams with 48 Gy in four fractions. Six of the eight patients received 3–4 cycles of chemotherapy using carboplatin (CBDCA) + etoposide (VP-16) or cisplatin (CDDP) + irinotecan (CPT-11). The follow-up period for all patients was 6–60 months (median: 32). Six patients were still alive without any recurrence. One patient died from this disease and one died from another disease. The overall and disease-specific survival rate at three years was 72% and 86%, respectively. There were no patients with local progression of the lesion targeted by SBRT. Only one patient had nodal recurrence in the mediastinum at 12 months after treatment. The progression-free survival rate was 71%. No Grade 2 or higher SBRT-related toxicities were observed. SBRT plus chemotherapy could be an alternative to surgery with chemotherapy for inoperable patients with Stage I small-cell lung cancer. However, further investigation is needed using a large series of patients. Oxford University Press 2013-01 2012-08-24 /pmc/articles/PMC3534277/ /pubmed/22923748 http://dx.doi.org/10.1093/jrr/rrs075 Text en © The Author 2012. Published by Oxford University Press on behalf of The Japan Radiation Research Society and Japanese Society for Therapeutic Radiology and Oncology. http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Oncology Shioyama, Yoshiyuki Nakamura, Katsumasa Sasaki, Tomonari Ohga, Saiji Yoshitake, Tadamasa Nonoshita, Takeshi Asai, Kaori Terashima, Koutarou Matsumoto, Keiji Hirata, Hideki Honda, Hiroshi Clinical results of stereotactic body radiotherapy for Stage I small-cell lung cancer: a single institutional experience |
title | Clinical results of stereotactic body radiotherapy for Stage I small-cell lung cancer: a single institutional experience |
title_full | Clinical results of stereotactic body radiotherapy for Stage I small-cell lung cancer: a single institutional experience |
title_fullStr | Clinical results of stereotactic body radiotherapy for Stage I small-cell lung cancer: a single institutional experience |
title_full_unstemmed | Clinical results of stereotactic body radiotherapy for Stage I small-cell lung cancer: a single institutional experience |
title_short | Clinical results of stereotactic body radiotherapy for Stage I small-cell lung cancer: a single institutional experience |
title_sort | clinical results of stereotactic body radiotherapy for stage i small-cell lung cancer: a single institutional experience |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3534277/ https://www.ncbi.nlm.nih.gov/pubmed/22923748 http://dx.doi.org/10.1093/jrr/rrs075 |
work_keys_str_mv | AT shioyamayoshiyuki clinicalresultsofstereotacticbodyradiotherapyforstageismallcelllungcancerasingleinstitutionalexperience AT nakamurakatsumasa clinicalresultsofstereotacticbodyradiotherapyforstageismallcelllungcancerasingleinstitutionalexperience AT sasakitomonari clinicalresultsofstereotacticbodyradiotherapyforstageismallcelllungcancerasingleinstitutionalexperience AT ohgasaiji clinicalresultsofstereotacticbodyradiotherapyforstageismallcelllungcancerasingleinstitutionalexperience AT yoshitaketadamasa clinicalresultsofstereotacticbodyradiotherapyforstageismallcelllungcancerasingleinstitutionalexperience AT nonoshitatakeshi clinicalresultsofstereotacticbodyradiotherapyforstageismallcelllungcancerasingleinstitutionalexperience AT asaikaori clinicalresultsofstereotacticbodyradiotherapyforstageismallcelllungcancerasingleinstitutionalexperience AT terashimakoutarou clinicalresultsofstereotacticbodyradiotherapyforstageismallcelllungcancerasingleinstitutionalexperience AT matsumotokeiji clinicalresultsofstereotacticbodyradiotherapyforstageismallcelllungcancerasingleinstitutionalexperience AT hiratahideki clinicalresultsofstereotacticbodyradiotherapyforstageismallcelllungcancerasingleinstitutionalexperience AT hondahiroshi clinicalresultsofstereotacticbodyradiotherapyforstageismallcelllungcancerasingleinstitutionalexperience |